Proceeds to be used for clinical trials, manufacturing and development
By Devika Patel
Knoxville, Tenn., July 1 – GlobeImmune, Inc. said it priced its $15 million initial public sale of stock with a $2.25 million greenshoe. The deal was announced March 17.
The company will sell 1.5 million common shares at $10.00 per share.
Aegis Capital Corp. is the sole bookrunning manager.
Celgene Corp., HealthCare Ventures VII, LP, Lilly Ventures Fund I, LLC and Morgenthaler Partners, VII, LP intend to participate.
Settlement is expected July 8.
Proceeds will be used for clinical trials, manufacturing, development, working capital and other general corporate purposes.
The biopharmaceutical company is based in Louisville, Colo. The company expects its shares will trade on the Nasdaq under the symbol “GBIM.”
| Issuer: | GlobeImmune, Inc.
|
| Issue: | Common stock
|
| Amount: | $15 million
|
| Greenshoe: | $2.25 million
|
| Shares: | 1.5 million
|
| Price: | $10.00
|
| Warrants: | No
|
| Bookrunner: | Aegis Capital Corp.
|
| Investors: | Celgene Corp., HealthCare Ventures VII, LP, Lilly Ventures Fund I, LLC and Morgenthaler Partners, VII, LP
|
| Announcement date: | March 17
|
| Pricing date: | July 1
|
| Settlement date: | July 8
|
| Stock exchange: | Nasdaq: GBIM
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
